Common use of Efficacy Endpoints Clause in Contracts

Efficacy Endpoints. [*] to be quantified in [*]. In the case, that no [*] are available, [*] are to be quantified in the peripheral blood. Any one of the following three endpoints: - [*] fold enrichment of gene modified T cells [*] weeks after treatment [*], or - proportion of [*] > [*], [*] weeks after treatment, or - [*] of [*] over the course of the clinical trial. [*] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. In addition, the following endpoint must also be met: -[*] from [*] following treatment. Efficacy endpoints shall apply for at least [*] out of [*] patients treated in Phase I/II Clinical Trial. [*] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. (1) License and Supply Agreement dated October 15, 1999 by and between XCYTE and Diaclone S.A., as amended (2) Non-Exclusive License Agreement dated October 20, 1999 by and between XCYTE and ▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ Cancer Research Center, as amended (3) License Agreement dated July 8, 1998 by and between XCYTE and Genetics Institute, L.L.C. (“GI”), as amended, including the exhibits: (A) License Agreement between GI and the Secretary of the Navy dated December 10, 1996, as amended, (B) License Agreement dated May 28, 1992 between GI and the University of Michigan, as amended, (C) License Agreement dated July 20, 1993 between GI (as successor-in-interest to Repligen Corporation) and ▇▇▇▇ ▇▇▇▇▇▇ Cancer Institute, as amended. Xcyte™ Dynabeads® Volume: Storage: Storage buffer: 10 ml Store at 2-8°C [*]